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Understanding the ecology of drug-resistant pathogens is essential for devising rational programs to preserve the
effective lifespan of antimicrobial agents and to abrogate epidemics of drug-resistant organisms. Mathematical models
predict that strain fitness is an important determinant of multidrug-resistant Mycobacterium tuberculosis transmission,
but the effects of strain diversity have been largely overlooked. Here we compared the impact of resistance mutations
on the transmission of isoniazid-resistant M. tuberculosis in San Francisco during a 9-y period. Strains with a KatG
S315T or inhA promoter mutation were more likely to spread than strains with other mutations. The impact of these
mutations on the transmission of isoniazid-resistant strains was comparable to the effect of other clinical determinants
of transmission. Associations were apparent between specific drug resistance mutations and the main M. tuberculosis
lineages. Our results show that in addition to host and environmental factors, strain genetic diversity can influence the
transmission dynamics of drug-resistant bacteria.
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Introduction
Drug resistance in Mycobacterium tuberculosis has been
encountered worldwide [1]. It has been postulated and
mathematical models suggest that drug resistance will
seriously impair global tuberculosis control efforts [2,3]. In
at least some areas, resistant strains are replacing susceptible
ones, leading to ‘‘hotspots’’ of drug resistance [4]. In other
areas the introduction of standard control programs has
interrupted transmission of drug-resistant strains [5]. Thus, it
is important to increase our understanding of the biology of
drug resistance to predict and prevent the future spread of
resistant strains.
The factors that determine the epidemiology of drug-
resistant organisms that can be inﬂuenced by human
behavior, such as patterns of antimicrobial usage, have been
studied extensively. There has been less analysis of the role of
intrinsic microbiologic factors, such as the relative ﬁtness of
drug-resistant strains. Ecological theory and mathematical
models suggest that the relative ﬁtness of drug-resistant
strains can profoundly affect the emergence and propagation
of these organisms [2,3,6,7].
In vitro models using non-pathogenic organisms have
shown that drug resistance–conferring mutations are usually
associated with a ﬁtness cost [8]. The degree to which the
mutation affects the ﬁtness of the organism varies with the
speciﬁc drug resistance mutation, the environment, and
genetic background of the strain [8–12]. Compensatory
evolution can ameliorate the ﬁtness effects of drug resistance
mutations [13–16]. However, it is unclear if such experimental
models can be extrapolated to explain the behavior of
pathogenic drug-resistant bacteria in human populations.
To date, epidemiological studies and surveillance of M.
tuberculosis have not fully resolved whether the transmission
dynamics of drug-resistant strains are different from drug-
sensitive strains. Most molecular epidemiological work has
focused on multidrug-resistant strains (resistant to at least
isoniazid and rifampin) of M. tuberculosis. In such studies,
multidrug-resistant strains have been associated with both
more and less ongoing transmission than sensitive strains
[17–20]. These discrepancies suggest that drug-resistant
strains may be heterogeneous and that drug resistance–
conferring mutations might have a variable impact on strain
ﬁtness. In the case of isoniazid resistance, there is some
laboratory and epidemiological evidence in support of this
[21–24]. Alternatively, the genetic background of a strain
might inﬂuence how it adapts to antibiotics.
In this study, we have used comprehensive molecular
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speciﬁc resistance-conferring mutations and strain genetic
background on the transmission dynamics of isoniazid-
resistant M. tuberculosis in a human population.
Results
Bacterial Strains and Resistance Profiles
This study was based on an ongoing population-based
molecular epidemiological study of tuberculosis transmission
in San Francisco [25]. For the study period, 1991–1999, 2,104
cases of tuberculosis were culture positive for M. tuberculosis.
Full drug susceptibility testing was performed on 2,081
(98.9%) isolates, which were all recovered from distinct
tuberculosis patients. Of these isolates, 298 (14.3%) were
initially resistant to at least one ﬁrst-line anti-tuberculosis
drug (Table 1). Resistance to isoniazid was the most common
form of drug resistance. Genetic characterization was
available for 152 (85.9%) of the 177 isoniazid-resistant
isolates. Among these 152 isolates with resistance to isoniazid,
with or without resistance to other drugs, 136 had unique
restriction fragment length polymorphism (RFLP) patterns.
16 isolates (10.5%) shared an RFLP pattern, drug resistance
phenotype, drug resistance–conferring mutation, and lineage
speciﬁc marker (see below) with at least one other isolate,
indicating they were linked in seven genetically distinct
isolate clusters. Therefore, there were a total of 143
genetically distinct isoniazid-resistant strains (clones), provid-
ing a large, genetically well- characterized and representative
group of strains from a deﬁned human population for
studying the biology of resistance.
Drug-Resistant Alleles
Resistance to isoniazed has been associated with various
chromosomal mutations, but those in katG, and in the
promoter regions of inhA, occur most frequently in clinical
isolates of M. tuberculosis [26,27]. katG encodes a catalase-
peroxidase that activates the prodrug isoniazid to its active
form and also acts as a virulence factor, protecting against
oxidative stress [28]. InhA, encoded by inhA, is a component
of FAS-II (fatty acid elongation system) that is required for
mycolic acid synthesis and is a target for isoniazid [29–31].
inhA promoter mutations result in isoniazid resistance
through up-regulation of inhA. Mutations in the ahpC
promoter have also been described in isoniazid-resistant
isolates, but are thought to be compensatory, helping strains
adjust to the additional oxidative stress imposed by mutations
in katG [32–34].
Sequencing of these three principal isoniazid resistance
loci of the 143 isoniazid-resistant strains revealed that 128
(89.5%) had at least one mutation in either the katG gene or
in the inhA promoter region (Table 2). Only 16 (11.2%) of
these strains had no resistance mutations in the regions
sequenced. After excluding the KatG L463R substitution, a
polymorphism not associated with isoniazid resistance [35],
92 strains (64.3%) were found to have katG gene mutations. 58
(40.6%) strains had the S315T mutation and a further 34
(23.8%) had other mutations affecting katG, including three
strains with complete gene deletions. inhA promoter muta-
tions were detected in 46 (32.2%) strains, of which 11 (7.7%)
also had a katG mutation. Characterization of the ahpC
promoter regions showed that mutations in this region were
uncommon, occurring in only 11 (7.7%) strains (Table 2).
Pertinently, none of these arose in strains without other
isoniazid resistance–conferring mutations, and ten of the 11
strains with mutations in the ahpC promoter region had
mutations in katG, including two of the strains with complete
gene deletions. These ﬁndings support the notion that ahpC
promoter mutations are in fact compensatory, rather than
causing resistance directly.
Transmission Dynamics of Drug Resistance–Conferring
Mutations
Genetic clustering has been used extensively in molecular
epidemiological studies as a measure for ongoing tuberculosis
transmission [36,37]. The underlying assumption is that in a
strict population-based study such as the one reported here,
Table 1. Primary Drug-Resistant Clinical Isolates of M. tuber-
culosis Isolated in San Francisco from 1991–1999
Resistance Profile Number
of Isolates
Genetically Characterized
Isolates
n (Percentage
of All)
n (Percentage of All
with This Profile)
EMB 3 (1.0) —
PZA 7 (2.3) —
RIF 27 (9.7) —
STR 84
a (28.2) —
INH 106
b (35.6) 90 (84.9)
INH þ RIF 13
c (4.7) 12 (92.3)
INH þ STR 47
d (15.8) 39 (83.0)
INH þ RIF þ STR 11
e (4.0) 11 (100)
Total 298 (100) 152 (85.9)
aIncludes one isolate resistant to EMB.
bIncludes four isolates that were also resistant to EMB, one isolate resistant to PZA, and
one isolate resistant to both EMB and PZA.
cIncludes three isolates resistant to both EMB and PZA and one isolate resistant to PZA
only.
dIncludes four isolates resistant to EMB and two isolates resistant to PZA.
eIncludes three isolates resistant to EMB and two isolates resistant to both EMB and PZA.
INH, isoniazid; RIF, rifampicin; STR, streptomycin; EMB, ethambutol; PZA, pyrazinamide.
DOI: 10.1371/journal.ppat.0020061.t001
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Synopsis
Resistance to antibiotics is an increasing global public health
problem. Multidrug-resistant tuberculosis is threatening the control
of this deadly infectious disease in many parts of the world. Studies
to identify the factors that lead to the emergence and subsequent
spread of drug-resistant organisms have clearly shown that patient
adherence to a 6 mo course of treatment is very important to
prevent the development of drug-resistant tuberculosis. However,
little is known about how bacterial genetics might influence the
spread of drug-resistant strains. This study showed that among the
strains in San Francisco with resistance to isoniazid, one of the main
anti-tuberculosis drugs, only certain strains were transmitted
effectively. The transmission of specific isoniazid-resistant strains
depended on the type of genetic mutation leading to resistance.
Also, isoniazid-resistant strains coming from different parts of the
world were associated with different resistance mutations. This
study’s results show that the spread of drug resistance is due to the
strain of tuberculosis as well as the environment and characteristics
of the patient, and may partially explain why some areas of the
world have worse drug resistance problems than others.tuberculosis patients harboring isolates with unique RFLP
patterns represent cases of reactivation of a latent infection,
whereas patients with genetically clustered isolates are
epidemiologically linked and represent chains of tuberculosis
transmission. This is based on more than a decade of
molecular epidemiological studies carried out in many
communities from different countries. Outbreaks of tuber-
culosis in health-care facilities, prisons, and other contained
situations have been shown to be caused by genetically
identical strains [38,39]. In addition, epidemiological links
have been demonstrated between genetically clustered strains
identiﬁed at the community level [40]. For example, a study
from Holland could establish an epidemiological link for 86%
of genetically clustered strains [41].
To determine the relationship between drug resistance
mutations and tuberculosis transmission dynamics, we com-
pared the percentage of genetic clustering in isolates
associated with the different drug resistance mutations (Table
2). Genetic clustering is usually based only on speciﬁc RFLP
ﬁngerprinting patterns. However, by including the pheno-
typic drug resistance proﬁle, the speciﬁc drug resistance
mutation, as well as the markers for the major M. tuberculosis
lineage (see below), we ensured a more stringent deﬁnition of
genetic clustering. The isoniazid-resistant isolates with
resistance mutations could be divided into three groups
(Table 2): those isolates with a mutation in KatG other than
the S315T (Group 1), those isolates with a KatG S315T
mutation (Group 2), and those isolates with a inhA-15;c-t
promoter mutation only (Group 3). Whereas isolates with
KatG mutations other than S315T were never genetically
clustered (Table 2), 11.3% of the KatG S315T mutants
(Fisher’s 2-tailed exact test: p , 0.05) and 17.8% of the
inhA-15;c-t promoter mutants (Fisher’s 2-tailed exact test: p ,
0.002) showed genetic clustering (Table 2). 11.7% of strains
without a deﬁned resistance mutation were genetically
clustered. No strains with ahpC promoter mutations were
genetically clustered.
These data demonstrate that only two isoniazid resistance
mutations were effectively propagated in San Francisco
during the study period. This is consistent with the role of
catalase-peroxidase (KatG) in the pathogenicity of M. tuber-
culosis, which is a known virulence factor [23,42]. KatG S315T
is an unusual substitution resulting in a functional enzyme
that retains catalase-peroxidase activity but with a diminished
Table 2. Isoniazid Resistance–Conferring Mutations and RFLP Clusters Identified in 152 Isoniazid-Resistant Isolates of M. tuberculosis
from San Francisco, 1991–1999
Group Mutations RFLP Clusters Clustered Isolates Unique Isolates Total Isolates Total Clones
n (%) n (%) n (%) n (%) n (%)
7 (100) 16 (100) 136 (100) 152 (100) 143 (100)
Group (1) KatG mutations
other than S315T
a
KatG S315N 0 0 2 (1.5) 2 (1.3) 2 (1.4)
KatG V1L, R104Q, A106V, W107R, A109V,
N138D, K143T, Y229F, A264T, K301aag_atag,
S315I, Y337C, K345T, T394A, D573N, W728C,
D735N, or Deletion
0 0 18 (13.2) 18 (11.8) 18 (12.6)
KatG D94G þ ahpC prom-34;g-a 0 0 1 (0.7) 1 (0.7) 1 (0.7)
KatG L384R þ ahpC prom-39;c-t 0 0 1 (0.7) 1 (0.7) 1 (0.7)
KatG S315N þ ahpC prom-10;c-a 0 0 1 (0.7) 1 (0.7) 1 (0.7)
KatG A636E þ ahpC prom-10;c-t 0 0 1 (0.7) 1 (0.7) 1 (0.7)
KatG L653P þ ahpC prom-6;g-a 0 0 1 (0.7) 1 (0.7) 1 (0.7)
KatG DEL
c þ ahpC prom-6;g-a 0 0 1 (0.7) 1 (0.7) 1 (0.7)
KatG DEL þ ahpC prom-15;c-t 0 0 1 (0.7) 1 (0.7) 1 (0.7)
KatG T85P, G121C, Y155C, A162T, T251M,
P280H, or E607K þ inhA prom-15;c-t
0 0 7 (5.1) 7 (4.6) 7 (4.9)
Subtotal 0 0 34 (25.0) 34 (22.4) 34 (23.8)
Group (2) KatG S315T
mutation
KatG S315T 3 (42.9) 7 (43.8) 48 (35.3) 55 (36.2) 51 (35.7)
KatG S315T þ inhA prom-15;c-t 0 0 3 (2.2) 3 (2.0) 3 (0.7)
KatG S315T þ inhA prom-17;g-t 0 0 1 (0.7) 1 (0.7) 1 (0.7)
KatG S315T þ ahpC prom 0;t-c 0 0 1 (0.7) 1 (0.7) 1 (0.7)
KatG S315T þ ahpC prom-6;g-a 0 0 1 (0.7) 1 (0.7) 1 (0.7)
KatG S315T þ ahpC prom-54;t-tatgt 0 0 1 (0.7) 1 (0.7) 1 (0.7)
Subtotal 3 (42.9) 7 (43.8) 55 (40.4) 62 (40.8) 58 (40.6)
Group (3) inhA prom-15;c-t
mutation
inhA prom-15;c-t 3 (42.9) 7 (43.8) 31 (22.8) 38 (25.0) 34 (23.8)
inhA prom-15;c-t þ ahpC prom-30 c-t 0 0 1 (0.7) 1 (0.7) 1 (0.7)
Subtotal 3 (42.9) 7 (43.8) 32 (23.5) 39 (25.7) 35 (24.5)
Other mutations or
no mutations
inhA prom-147 c-t 0 0 1 (0.7) 1 (0.7) 1 (0.7)
No mutations 1 (14.3) 2 (12.5) 14 (10.3) 16 (10.5) 15 (10.5)
Subtotal 1 (14.3) 2 (12.5) 15 (11.0) 17 (11.2) 16 (11.2)
aExcluding the KatG L463R polymorphism.
prom, promoter.
DOI: 10.1371/journal.ppat.0020061.t002
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Transmission of INH-Resistant M. tbcapacity to activate isoniazid [23,43,44]. Similarly, the inhA-
15;c-t promoter mutation does not affect KatG activity. This
is in contrast to the other substitutions in, or deletions of,
katG, which have a more profound effect on enzyme activity
[23,42], although all of the mutations identiﬁed in this study
have not been empirically evaluated. Thus, KatG activity
could explain the different transmission dynamics of the
various mutations.
Because resistance to additional drugs could inﬂuence the
ﬁtness of isoniazid-resistant strains in an unpredictable
manner, we repeated our analysis on the 90 isolates resistant
to isoniazid alone (Table 1). We found that 7/28 (25.0%) of the
isolates with the KatG S315T mutation and 4/23 (17.4%) with
the inhA-15;c-t were genetically clustered. The comparisons to
the group of isolates with other katG mutations remained
statistically signiﬁcant (Fisher’s 2-tailed exact test: p , 0.02
and p , 0.05, respectively).
To assess the importance of speciﬁc mutations for the
propagation of isoniazid-resistant strains, compared to other
factors generally considered in conventional molecular
epidemiologic studies, we performed univariate and multi-
variate analyses. The univariate analysis showed that isoniazid
resistance due to mutations from Group 2 or 3, which are
likely to maintain KatG activity, was the third strongest risk
factor for genetic clustering (Table 3). In the ﬁnal multi-
variate logistic regression model, these mutations perfectly
predicted genetic clustering because all genetically clustered
isolates had Group 2 or 3 mutations. Only homelessness
remained an independent risk factor for genetic clustering
(adjusted odds ratio ¼ 9.6, 95% conﬁdence interval: 1.7–53.3,
p ¼ 0.01). Taken together, these results indicate that speciﬁc
drug resistance mutations have an impact on the successful
propagation of isoniazid-resistant tuberculosis, as great or
greater than other well-recognized risk factors, such as the
presence of acid-fast bacilli in sputum smears.
Strain Lineage and Drug Resistance–Conferring Mutations
The global population structure of M. tuberculosis consists of
six main phylogenetic lineages [45]. These lineages can be
deﬁned by single nucleotide polymorphisms and large
sequence polymorphisms, which in M. tuberculosis behave as
unique event polymorphisms, and therefore allow for robust
phylogenetic inference [46,47]. To evaluate the inﬂuence of
strain genetic background on the genetics of resistance,
associations between strain lineage and isoniazid resistance–
conferring mutations were sought. All of the 152 isoniazid-
resistant isolates were screened for lineage-speciﬁc genetic
markers and classiﬁed as belonging to the East-Asian lineage,
the Indo-Oceanic lineage, or the Euro-American lineage [45].
Of the strains examined in this way, 37 (24.3%) belonged to
the East-Asian lineage, 51 (33.6%) to the Indo-Oceanic
lineage, and 64 (42.1%) to the Euro-American lineage. After
exclusion of ten isolates harboring a combination of katG and
inhA promoter mutations (Table 2), we found statistically
signiﬁcant associations between the three lineages and the
three groups of isoniazid-resistance mutations (Table 4). The
East-Asian lineage was associated with KatG mutations other
than S315T, the inhA promoter mutation occurred signiﬁ-
cantly more frequently among the Indo-Oceanic lineage, and
the Euro-American lineage was associated with the KatG
S315T mutation. These associations suggest that genetic
differences between the strain lineages could inﬂuence their
propensity for different mutations.
We previously showed that within San Francisco, strains
belonging to the Euro-American lineage were more likely to
result in secondary cases than strains from other lineages [45].
In order to control for this potential confounding factor, we
repeated our analysis of transmission and included only the
64 isolates belonging to the Euro-American lineage. We
found that 14 out of 52 isolates (26.9%) with isoniazid-
resistance mutations from Group 2 and 3 were genetically
clustered, whereas none of the 12 isolates with other katG
mutations were genetically clustered (Fisher’s 2-tailed exact
test:p¼ 0.0539).
Discussion
Isoniazid resistance is caused by several distinct mecha-
nisms, and data from animal models indicate there are
variations in the pathogenicity of isoniazid-resistant strains
[22,23]. As reported here, differences are also apparent in
human tuberculosis, as among mutations in KatG only the
S315T mutation was associated with secondary cases. In
contrast, strains with other mutations in katG did not produce
a single secondary case in the population during the 9-y study
period. Catalase-peroxidase encoded by katG transforms the
prodrug isoniazid into its bioactive form, as well as protecting
Table 3. Results of the Univariate Analysis Showing Host and
Bacterial Factors Associated with Clustering in 152 Isoniazid-
Resistant Isolates of M. tuberculosis from San Francisco
Risk Factor
Number of
Patients (%)
Number of
Patients in
Clusters (%)
Odds Ratio
(95% CI) P
Group (2) and (3)
mutations
118 (77.6) 16 (13.6) 5.8 (0.84–248)
a 0.023
b
Male sex 97 (63.8) 12 (12.4) 1.8 (0.51–8.04) 0.416
b
Age   43 y 78 (51.3) 4 (5.1) 0.3 (0.06–0.99) 0.034
b
Birth in the United
States
29 (19.1) 9 (31.0) 7.5 (2.2–26.1) ,0.001
Ethnicity
c
Asian 104 (68.9) 5 (4.8) 0.2 (0.04–1.1) 0.037
b
Black 8 (5.3) 2 (25.0) 1.3 (0.1–12.4) .0.99
b
Hispanic 19 (12.6) 4 (21.1) 1.1 (0.17–6.9) .0.99
b
White 20 (13.2) 4 (20.0) Reference Reference
HIV-positive 19 (12.5) 4 (21.1) 2.7 (0.56–10.4) 0.119
b
Homelessness 10/120
d (8.3) 3 (30.0) 7.4 (0.97–44.0) 0.027
b
Substance abuse 17 (11.2) 4 (23.5) 3.2 (0.64–12.4) 0.084
b
Pulmonary tuberculosis 135 (88.8) 14 (10.4) 0.87 (0.17–8.6) 0.695
b
Sputum smear
AFB-positive
70 (46.1) 7 (10.0) 0.85 (0.25–2.7) 0.764
Cavitary disease 23 (15.1) 1 (4.4) 0.35 (0.01–2.5) 0.468
b
Streptomycin resistance 50 (32.9) 3 (6.0) 0.44 (0.08–1.7) 0.267
b
Rifampin resistance 23 (15.1) 0 (0.0) 0.28 (0.006–2.0)
a 0.132
b
Comparisons were performed using the v
2 test of proportions unless otherwise noted.
aAll of the isolates with Group 2 and 3 mutations were in genetic clusters. Because of the
resulting zero value in one of the cells of the corresponding 2 by 2-table, the value 1 was
therefore added to each cell in order to be able to calculate an odds ratio.
bTwo-tailed Fisher’s exact test.
cExcludes one American Indian. Odds ratio and P values are from the comparison with
Whites.
dDenominator is smaller due to missing values.
AFB, acid-fast bacilli; CI, confidence interval.
DOI: 10.1371/journal.ppat.0020061.t003
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Transmission of INH-Resistant M. tbbacteria against oxidative stress encountered during host
infection [28]. Loss of KatG activity is therefore usually
associated with reduced virulence [23]. Our data are
consistent with the ﬁndings of in vitro and in vivo experi-
ments showing that isogenic mutants with the KatG S315T
substitution retain KatG activity and associated virulence in
mice [23,43,44]. Recently, the crystal structure of KatG has
shown how the S315T mutation could block binding of
isoniazid without interfering with catalysis [48]. Only one
other mutation, the S275T, has been evaluated in mice and
has been found to be of low virulence [23]. However, because
all of the KatG mutations identiﬁed in this study have not
been functionally characterized, and some do not abolish
enzymatic activity completely, it therefore remains possible
that other characteristics linked to both the KatG S315T and
inhA promoter mutations could account for the differences in
transmission between mutants. Nevertheless, our results
suggest that only the KatG S315T mutant retains sufﬁcient
levels of catalase-peroxidase activity to be effectively propa-
gated within the study setting.
Mutations in the inhA gene promoter were also associated
with secondary cases. There is no obvious explanation of how
inhA promoter mutations might affect pathogenicity, but they
have not been formally evaluated in animal models. Muta-
tions intrinsic to the inhA gene have been formally tested and
do not affect pathogenicity [49]. Mutations in the promoter
of ahpC are thought to compensate for the loss of KatG
activity in isoniazid-resistant strains through up-regulation of
ahpC that encodes a putative alkyl hydroperoxide reductase
[32–34]. This notion is supported by our study, as ten out of
11 isolates with ahpC promoter mutations were found to have
mutations or deletions in katG. None of these double mutants
were genetically clustered, indicating that ahpC promoter
mutations are not essential or important for the transmission
of isoniazid-resistant strains. Other genetic mechanisms of
resistance to isoniazid exist that were not examined here, but
these occur infrequently in clinical isolates and are therefore
unlikely to be the basis for our results [26].
Mutational events are generally random and individual
tuberculosis patients can harbor subpopulations of the same
mycobacterial clone with different drug resistance–confer-
ring mutations [50]. However, studies have shown that there
seems to be a strong selection for low-cost drug resistance
mutations in vivo [10,12,51]. The fact that the KatG S315T
and the inhA-15;c-t mutations were associated with secondary
cases in San Francisco suggests that selection for low-cost
mutations in humans may also occur through successful
transmission. This is consistent with other studies reporting
these two mutations as the clinically most common isoniazid
resistance mutations [27,52,53].
An obvious question posed by these results is how the KatG
S315T and inhA promoter mutants compare to fully
susceptible strains. A number of potential confounders make
comparisons between resistant and drug-sensitive strains
problematic [51,54]. For example, the use of additional
genetic and phenotypic markers to epidemiologically link
the drug-resistant strains will reduce cluster size in this
group. Nevertheless, despite the effective tuberculosis control
program in San Francisco [21], the KatG S315T and inhA
promoter mutants were still transmitting and causing
secondary cases of drug-resistant M. tuberculosis. Therefore,
in less successful programs, or in areas where resistance
testing and individualized treatment are not available, a
longer period of infectiousness of patients will result in
dissemination of these strains.
In addition to showing that drug resistance mutations are
affecting pathogenicity, our results demonstrate a second
means by which bacterial genetics are inﬂuencing the
emergence of drug-resistant tuberculosis. We found that
different strain lineages were associated with distinct
isoniazid resistance mutations. These lineages are dominant
in speciﬁc geographical areas where the patients are likely to
have acquired their tuberculosis infection [45,46]. Differing
tuberculosis control and patient adherence practices in each
region could favor the emergence of speciﬁc drug resistance
mutations. However, this seems unlikely as the East-Asian
strains were from patients originally from a geographically
wide area, including Vietnam, China, and Hong Kong,
throughout which treatment practices will have varied. An
alternative explanation is that there are genetic differences
between the strain lineages that inﬂuence their adaptation to
isoniazid, as has been observed in other bacteria [11]. For
example, the association of the East-Asian lineage, with KatG
mutations predicted to be poorly functional, suggests this
lineage may be better able to adapt to increases in oxidative
stress. Interestingly, a recent study has shown that members
of the East-Asian strain lineage produce a phenolic glycolipid
that inhibits the innate immune response [55], which might
affect the oxidative burst generated by host immunity [28].
Other studies have failed to demonstrate similar associa-
tions between speciﬁc drug resistance mutations and strain
genotypes [56]. This discrepancy is most likely due to the
different genetic markers used to deﬁne the different
mycobacterial lineages. Traditional mycobacterial genotyp-
ing techniques used in epidemiological studies of tuberculosis
transmission are based on mobile or repetitive genetic
Table 4. Association between Three M. tuberculosis Strain Lineages and Three Classes of Isoniazid Resistance–Conferring Mutations
Mutation
East-Asian Lineage
(n ¼ 36) n (%)
Indo-Oceanic Lineage
(n ¼ 45) n (%)
Euro-American Lineage
(n ¼ 61) n (%)
Odds Ratio
(95% CI)
a P
KatG mutations other than S315T 15 (41.7) 2 (4.4) 10 (16.4) 5.6 (2.1–15.1) , 0.001
KatG S315T 13 (36.1) 15 (33.3) 31 (50.8) 2.0 (0.94–4.1) 0.0517
inhA promotor-15;c-t 5 (13.9) 21 (46.7) 13 (21.3) 3.8 (1.6–9.0) , 0.001
No/other mutation 3 (8.3) 7 (15.6) 7 (11.5) — —
aFor each lineage, the v
2 test was used to compare the proportion of the most frequent mutation to its proportion in the two other lineages combined.
DOI: 10.1371/journal.ppat.0020061.t004
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the high discriminatory power of these techniques. However,
because of this fast molecular clock, similar DNA patterns can
emerge in phylogenetically unrelated strains (homoplasy),
making it difﬁcult to infer deep phylogenetic groups
unambiguously [46,58–61]. To our knowledge, only one other
study has used unique event polymorphisms to deﬁne strain
lineages in a large collection of drug-resistant strains. In their
study, Baker and colleagues deﬁned major strain lineages
using synonymous single nucleotide polymorphisms [47].
Consistent with our ﬁndings, Baker and co-workers reported
the same association between the Indo-Oceanic lineage
(corresponding to Lineage IV in the study by Baker et al.)
and the inhA promoter-15c-t mutation. No association with
the East-Asian lineage was found in the study by Baker et al.,
probably because of the limited number of East-Asian strains
that were included [47].
The study presented here is based on the assumption that
genetic clustering is an accurate measure of ongoing tuber-
culosis transmission. Although there is a wealth of published
evidence in support of this [25,36–41], alternative hypotheses
can be envisaged. For example, certain combinations of strain
genetic background and resistance mutations could result in
hyper-virulence leading to rapid progression and a greater
probabilityofdiagnosisandinclusioninthestudy.Thiscannot
be ruled out, but is unlikely, as the transmission dynamics of
the three main genetic lineages in San Francisco have been
studied and considered here [45]. Furthermore, 85% of all
isoniazid-resistant isolates collected during a 9-y period by
population-based sampling were included in this study, so
systematic exclusion of speciﬁc genotypes is also unlikely.
In conclusion, our study shows that in addition to well-
described clinical determinants of tuberculosis transmission,
bacterial genetics also have an important impact on the
propagation of drug-resistant M. tuberculosis. Further work is
required to establish whether these ﬁndings can be extended
to other classes of anti-tuberculosis drugs and to other
settings such as those with high rates of transmission where
host susceptibility is altered by HIV infection. Ultimately, a
complete understanding of drug resistance will require the
integration of host factors, patterns of antibacterial usage, as
well as bacterial genetics.
Materials and Methods
Study population. The epidemiological methods and study
population have been described previously [21,25]. All patients from
San Francisco who met the Centers for Disease Control and
Prevention criteria as an incident case of tuberculosis during the
years 1991–1999 were included in the study population. There were
2,498 tuberculosis cases reported, 2,142 (85.7%) were culture positive,
and 2,104 (98.2%) were identiﬁed as M. tuberculosis.
Drug resistance testing. All M. tuberculosis isolates from incident
cases of tuberculosis were tested for drug susceptibility using
standard BACTEC methods. The following concentrations were used
to deﬁne resistance: isoniazid 0.1 mg/l, rifampicin 2 mg/l, streptomy-
cin 2 mg/l, and ethambutol 2.5 mg/l. When detected, drug resistance
was conﬁrmed with culture on solid media. Patients infected with
strains that were initially fully susceptible, but who subsequently
developed resistant strains, were not included in this study.
Molecular epidemiology. Standard epidemiologic data were col-
lected as part of a prospective population-based molecular epide-
miologic study of tuberculosis in San Francisco [25]. For each isolate,
genomic DNA was extracted from 10-ml liquid cultures and sub-
cultured from the initial Lowenstein Jensen slope used for the
primary isolation. RFLP typing was performed following stand-
ardized procedures [57], with patterns entered and analyzed using a
BioImage Whole Band Analyzer software (version 9 3.3, BioImage
Corporation, Ann Arbor, Michigan, United States). Isolates with
fewer than six copies of IS6110 were further genotyped using
polymorphic GC-rich sequence (PGRS) RFLP [57]. For the majority of
isolates an aliquot of this original DNA was preserved at  20 8C and
was used as a template for amplifying resistance genes. In a few cases
isolates were re-cultured from  80 8C stocks preserved in glycerol.
The protocols and the procedures for the protection of human
participants were approved by Stanford University and the Univer-
sity of California, San Francisco.
Isolates with the same RFLP genotype (6 one IS6110 band for
strains with . 5 bands; 6 one IS6110 band and identical PGRS
patterns in isolates with , 6I S 6110 copies), the same drug resistance
proﬁle, the same drug resistance–conferring mutation, and belonging
to the same M. tuberculosis lineage were considered genetically
clustered and part of a chain of transmission. Isolates that differed
in any of these criteria were considered unique and not linked
epidemiologically. Two isolates were classiﬁed as clustered based on
the RFLP pattern and drug resistance proﬁle.
Sequencing of drug resistance genes. To determine the mutations
responsible for isoniazid resistance in each isolate, known resistance
genes were sequenced. Oligonucleotide primers were designed for
the ampliﬁcation and sequencing of the entire furA-katG locus
(H37Rv: 2153626–2156657, 3,031 bp), the promoter region of inhA
(H37Rv: 1673196–1673653, 457 bp), and the oxyR-ahpC intergenic
region (H37Rv: 2726390–2725888, 502 bp). DNA was ampliﬁed in a
25-ll reaction using a GeneAmp system 9700 thermocycler (Applied
Biosystems, Foster City, California, United States). Unincorporated
nucleotides and primers were removed by ﬁltration with Multiscreen-
PCR plates (Millipore, Billerica, Massachusetts, United States).
Sequencing reactions were performed with the ET Terminator
sequencing kit (Amersham Biosciences, Little Chalfont, United
Kingdom) and puriﬁed in Multiscreen plates (Millipore) with
Sephadex (Amersham Biosciences). Sequence data were generated
with an ABI 377 automated sequencer (Applied Biosystems) at the
PAN facility, Stanford University (http://cmgm.stanford.edu/pan) and
analyzed with SeqMan (DNASTAR, Inc.).
Determination of strain lineage by multiplex real-time PCR. The
population structure of M. tuberculosis in San Francisco consists of
three main phylogenetic lineages [45]. To determine if the study
isolates belonged to either the East-Asian lineage, the Indo-Oceanic
lineage, or the Euro-American lineage, the corresponding lineage
speciﬁc markers were targeted by multiplex real-time PCR as
reported previously [45,62,63]. The three lineages were deﬁned based
on the absence of the region of difference (RD) 105, absence of
RD239, and the ctg to cgg substitution at KatG463, respectively.
Statistical analysis. To explore the relationship between RFLP
clustering and clinical, demographic, and bacterial variables, uni-
variate analyses using the v
2 test of proportions or the 2-tailed
Fisher’s exact test and multivariate logistic regression modeling were
performed. All variables with a p-value   0.2 in the univariate
analysis and biological plausibility were considered for the multi-
variate logistic regression model. We performed forward stepwise
model construction and compared the log likelihood ratios of
successive models until the ﬁnal, most parsimonious model was
identiﬁed [64]. We also tested the signiﬁcance of potential interaction
terms. Statistical analyses were performed with Stata (version 7E;
Stata Corporation, College Station, Texas, United States).
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